The use of anticoagulants in patients hospitalised with COVID-19

Abstract

In this Cochrane Corner, we highlight the main findings of a Cochrane Review by Flumignan et al. entitled ‘Anticoagulants for people hospitalised with COVID‐19’ and discuss the implications of these findings for research and practice in South Africa. In particular, we underscore the need for additional, high‐quality, randomised controlled trials comparing different intensities of anticoagulation in patients with COVID‐19 illness. Individuals in the intensive care unit and those hospitalised with another illness who are incidentally found to be infected with SARS‐CoV‐2 should still only be treated with prophylactic‐dose low‐molecular‐weight heparin.

Keywords

• covid-19
• anticoagulation
• low molecular weight heparin
• south africa